Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19515805rdf:typepubmed:Citationlld:pubmed
pubmed-article:19515805lifeskim:mentionsumls-concept:C0014257lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C0341697lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C0002986lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C0427579lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C0441509lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:19515805lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:19515805pubmed:issue10lld:pubmed
pubmed-article:19515805pubmed:dateCreated2009-9-22lld:pubmed
pubmed-article:19515805pubmed:abstractTextIn Fabry disease, storage of globotriaosylceramide (Gb3) in arterial walls is one of the main pathogenetic factors that are thought to underlie the clinical manifestations of the disease. Abnormalities of the vessel wall, haemodynamics and pro- and anticoagulant factors may play a role, though the exact pathophysiology is incompletely understood. In this study, we try to clarify inconsistencies regarding coagulation activation, fibrinolysis, platelet activation and endothelial activation in 36 patients with Fabry disease.lld:pubmed
pubmed-article:19515805pubmed:languageenglld:pubmed
pubmed-article:19515805pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19515805pubmed:citationSubsetIMlld:pubmed
pubmed-article:19515805pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19515805pubmed:statusMEDLINElld:pubmed
pubmed-article:19515805pubmed:monthOctlld:pubmed
pubmed-article:19515805pubmed:issn1460-2385lld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:BoeyM LMLlld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:AertsJohannes...lld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:NieuwlandRien...lld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:HollakCarla...lld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:VedderAnouk...lld:pubmed
pubmed-article:19515805pubmed:authorpubmed-author:SturkGuusGlld:pubmed
pubmed-article:19515805pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19515805pubmed:volume24lld:pubmed
pubmed-article:19515805pubmed:ownerNLMlld:pubmed
pubmed-article:19515805pubmed:authorsCompleteYlld:pubmed
pubmed-article:19515805pubmed:pagination3074-81lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:meshHeadingpubmed-meshheading:19515805...lld:pubmed
pubmed-article:19515805pubmed:year2009lld:pubmed
pubmed-article:19515805pubmed:articleTitlePlasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment.lld:pubmed
pubmed-article:19515805pubmed:affiliationDepartment of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:19515805pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19515805lld:pubmed